Company profile
MBX BIOSCIENCES, INC.
NASDAQ:MBXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CANVUPARATIDE | phase3 | — | 4 | active |
| IMAPEXTIDE | phase2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07142707 | phase1 | recruiting | 2025-09-03 | 2026-10-30 | MBX Biosciences | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity |
| NCT07699471 | phase3 | recruiting | 2026-08-26 | 2028-01-01 | MBX Biosciences | A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism |
| NCT06531941 | phase2 | active_not_recruiting | 2024-10-31 | 2028-05-01 | MBX Biosciences | Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism |
| NCT06496217 | phase1 | completed | 2024-06-13 | 2025-09-04 | MBX Biosciences | Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function |
| NCT06465108 | phase2 | completed | 2024-08-08 | 2025-05-23 | MBX Biosciences | Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism |
FDA applications (0)
No records yet.